ACT 265.40 Actavis Inc $ACT Hit a 52 week high of
Post# of 91
Posted On: 11/20/2014 10:05:28 AM
ACT 265.40 Actavis Inc $ACT Hit a 52 week high of 267.20 Closing the day 09:45 at 265.40 -0.64 -0.24% With a day low of 264.45 and a total volume of 372,634.
ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
The Crucial Thing You're Missing About Many Dividend Stocks
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 29 mins ago
It's been proved time and time again that investing for the long haul is a better way to build wealth than short-term trading is. It's also been shown that dividend-paying stocks outperform their non-dividend-paying peers. When it comes down to...
ACT: 265.20 (-0.84), PFE: 30.33 (-0.11), AZN: 74.03 (-1.35), BMY: 58.36 (-0.45)
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 55.61 (-0.29), KOG: 10.00 (+0.24), MEAS: 86.00 (+0.01), HHC: 147.57 (+1.65), AET: 85.43 (-0.12), DLPH: 71.03 (-0.07), DLTR: 66.27 (+3.64), AEM: 26.63 (+0.58), AUXL: 33.07 (+0.04), DG: 66.62 (+0.52), ABBV: 65.14 (-0.36), DXM: 8.13 (-0.13), MNK: 84.81 (-1.17), ATHL: 58.40 (unch), NCQ: 0.71 (+0.02), COV: 96.81 (-0.69), AU: 9.61 (+0.27), MYL: 55.14 (-0.54), IAG: 2.28 (+0.07), FDO: 78.47 (+0.02), MGM: 22.16 (-0.03), GNW: 9.18 (+0.05), HIG: 40.71 (-0.09), NG: 2.89 (+0.09), EQIX: 223.23 (-2.45), HSH: 62.96 (unch), OAS: 26.59 (+0.74), PETM: 77.61 (-0.58), ACT: 265.20 (-0.84), MDT: 71.07 (-0.69), BPOP: 31.73 (-0.27), ENZY: 8.64 (+0.24), FCX: 27.97 (-0.11), GFI: 4.37 (+0.28), CZR: 16.22 (+1.85), CVC: 19.03 (+0.10), CIE: 10.44 (+0.31), CACQ: 10.22 (+0.03), AGN: 212.01 (-0.58), ECA: 18.14 (+0.34), FCH: 10.00 (-0.06), R: 90.35 (-0.20), DTV: 87.09 (-0.13), KMDA: 3.40 (+0.01), ANV: 1.68 (+0.19), MOVE: 20.95 (-0.03), BAC: 16.96 (-0.10), GRFS: 36.43 (+0.05), POST: 35.62 (+0.08), HCA: 66.47 (-0.57), RDN: 16.72 (-0.01), BEE: 12.84 (-0.10), CPWR: 10.23 (+0.07), GLD: 114.65 (+0.97), RLGY: 42.71 (-0.23), MTG: 8.96 (-0.01), HMHC: 20.00 (+0.06), CMCSA: 54.38 (unch), CBS: 53.21 (-0.13), BABA: 108.16 (-0.66)
Valeant Rises After Allergan Snub; Zeltiq In Buy Area
at Investor's Business Daily - Wed Nov 19, 5:14PM CST
Valeant Pharmaceuticals (VRX) hasn't missed a beat despite its failed takeover bid for Botox maker Allergan (AGN). Valeant lost out Monday to a competing bid from generic drugmaker Actavis (ACT), which said it would buy Allergan for $66 billion. Yet...
AGN: 212.01 (-0.58), ACT: 265.20 (-0.84), VRX: 143.00 (+0.53), ZLTQ: 28.24 (+0.12)
Mallinckrodt Q4 Earnings Beat Views, But Outlook Hazy
at Investor's Business Daily - Wed Nov 19, 4:35PM CST
Specialty drugmaker Mallinckrodt early Wednesday beat analysts' expectations handily with its fiscal Q4 report, but the stock fell 3.2% after the company put off providing hoped-for guidance in the wake of a Food and Drug Administration decision that...
MNK: 84.81 (-1.17), JNJ: 108.04 (-0.72), ACT: 265.20 (-0.84)
Celgene Up on Encouraging Long-Term Phase III Otezla Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 4:10PM CST
Celgene announced results from long-term efficacy and safety analyses from two phase III studies on Otezla.
ACT: 265.34 (-0.70), AMAG: 34.88 (-0.28), BMY: 58.33 (-0.48), CELG: 106.64 (-0.34)
Mallinckrodt Earnings Beat But No New Guidance
at Investor's Business Daily - Wed Nov 19, 10:42AM CST
Specialty drugmaker Mallinckrodt beat analysts' expectations handily in its fiscal Q4 report, but it didn't provide hoped-for guidance in the wake of an FDA decision that hits one of its best-selling drugs. Mallinckrodt (MNK) stock was down 4% in...
MNK: 84.81 (-1.17), JNJ: 108.04 (-0.72), ACT: 265.34 (-0.70), COV: 96.81 (-0.69)
Stock Market News for November 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 9:10AM CST
Rally in healthcare stocks and easing global growth worries boosted benchmarks to finish in the green on Tuesday
URBN: 30.41 (+0.88), AGN: 212.01 (-0.58), HD: 96.96 (+0.26), ACT: 265.34 (-0.70), GILD: 101.82 (-0.52), PFE: 30.33 (-0.11), COV: 96.81 (-0.69), ALXN: 191.08 (-0.88)
Critical Alerts For Gold Fields, Actavis, Trina Solar Limited, Alcoa and Herbalife Released By InvestorsObserver
PR Newswire - Wed Nov 19, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for GFI, ACT, TSL, AA and HLF.
HLF: 38.54 (-0.12), AA: 16.68 (-0.01), ACT: 265.34 (-0.70), GFI: 4.37 (+0.28), TSL: 10.58 (+0.08)
Cramer's Mad Money - PPG Industries Will Blow Right Through Its All-Time High (11/18/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 19, 4:30AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 18. CEO Interview: Chuck Bunch, PPG Industries (NYSE: PPG ) PPG Industries ( PPG ) has been a consistent performer. It has dominance in the...
AGN: 212.01 (-0.58), GPRO: 73.75 (-5.34), HD: 96.96 (+0.26), ACT: 265.34 (-0.70), BX: 32.59 (-0.08), S: 4.76 (+0.05), HAL: 48.67 (+0.24), M: 62.50 (+0.53), COP: 72.69 (+0.56), GPS: 39.88 (+0.34), BRK.B: 145.13 (-0.52), PPG: 210.74 (+0.08), BHI: 63.84 (+0.33)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 265.34 (-0.70), QLTI: 3.96 (-0.03), VRX: 143.00 (+0.53), AGN: 212.01 (-0.58), SHPG: 207.50 (-0.08), AUXL: 33.07 (+0.04), ABBV: 65.14 (-0.36), SNY: 46.50 (-1.59), ABT: 43.15 (-0.28), ENDP: 69.25 (+0.24), AKRX: 37.81 (-0.37), PFE: 30.33 (-0.11), INCY: 71.18 (-0.12), SLXP: 103.38 (-0.25), MYL: 55.14 (-0.54), AMGN: 162.98 (+0.34), LLY: 66.65 (-0.56), GSK: 46.33 (+0.08), BMY: 58.31 (-0.50), ACHN: 12.91 (unch), MRK: 58.93 (-0.71), AZN: 74.03 (-1.35), ICPT: 154.60 (-1.33), TEVA: 57.24 (-0.01), NVS: 95.21 (-0.52)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 265.34 (-0.70), QLTI: 3.96 (-0.03), VRX: 143.00 (+0.53), AGN: 212.01 (-0.58), SHPG: 207.50 (-0.08), AUXL: 33.07 (+0.04), ABBV: 65.14 (-0.36), SNY: 46.50 (-1.59), ABT: 43.15 (-0.28), ENDP: 69.25 (+0.24), AKRX: 37.81 (-0.37), PFE: 30.33 (-0.11), INCY: 71.18 (-0.12), SLXP: 103.38 (-0.25), MYL: 55.14 (-0.54), AMGN: 162.98 (+0.34), LLY: 66.65 (-0.56), GSK: 46.33 (+0.08), BMY: 58.31 (-0.50), ACHN: 12.91 (unch), MRK: 58.93 (-0.71), AZN: 73.99 (-1.39), ICPT: 154.60 (-1.33), TEVA: 57.24 (-0.01), NVS: 95.21 (-0.52)
Pharma ETFs In Focus On Allergan Takeover Deal
Zacks Funds - at Seeking Alpha - Tue Nov 18, 9:04PM CST
The healthcare space is witnessing 2014 as another banner year thanks to encouraging industry trends, solid corporate earnings and huge levels of merger and acquisition activities. The sector is clearly leading the broad market rally and this trend...
IHE: 146.79 (-0.73), AGN: 212.01 (-0.58), PPH: 64.85 (-0.50), ACT: 265.34 (-0.70), XPH: 109.85 (-0.48)
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous
at The Street - Tue Nov 18, 7:10PM CST
It's hard to be skeptical about high-flying stocks when the bulls are making money right now, Cramer says.
MMM: 158.24 (-0.59), AMZN: 325.43 (-1.11), JEC: 47.60 (+0.40), ACT: 265.34 (-0.70), HD: 96.96 (+0.26), BX: 32.59 (-0.08), DPLO: 25.01 (+0.51), UNH: 96.23 (-0.63), DECK: 94.62 (+0.10), COLM: 43.73 (+0.06), ALKS: 53.85 (-0.41), ADT: 35.41 (+0.04), CELG: 106.64 (-0.34), VE: 17.72 (-0.33), URBN: 30.41 (+0.88), AGN: 212.01 (-0.58), HLT: 25.20 (-0.32), AA: 16.68 (-0.01), RIG: 25.73 (+0.37), WMB: 55.50 (+0.28), PF: 32.99 (+0.09), PPG: 210.74 (+0.08), WPZ: 53.22 (+0.10)
Actavis'
at Investor's Business Daily - Tue Nov 18, 5:42PM CST
Actavis' (ACT) $66 bil takeover of Allergan (AGN) gets activist investor William Ackman's support, said Reuters. Ackman will reportedly withdraw a special shareholder meeting request at Allergan. Actavis shares jumped 8.7% to 269.60. Allergan rose 2%...
AGN: 212.01 (-0.58), ACT: 265.34 (-0.70)
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 265.50 (-0.54), CLDX: 19.52 (+0.79), ABBV: 65.14 (-0.36)
Vipshop, Jack in the Box Rise In After-Hours Trading
at Investor's Business Daily - Tue Nov 18, 4:04PM CST
Stocks finished higher Tuesday, with the Dow Jones industrial average and the S&P 500 making fresh all-time highs and the Nasdaq overcoming Monday's weakness with a 14 1/2-year high. Volume was higher than Monday on the NYSE and slightly lower on the...
AGN: 212.01 (-0.58), JACK: 75.86 (+0.94), ACT: 265.50 (-0.54), VIPS: 22.24 (-0.20)
Market News: Actavis Plc, SunEdison Inc, Halliburton Company
at The Street - Tue Nov 18, 3:54PM CST
Investors' confidence on the U.S. economy increased due to better-than-expected corporate earnings and economic data The stock markets in the United States rallied amid investors' speculation that...
ACT: 265.50 (-0.54), TERP: 31.77 (-0.15), SUNE: 21.63 (+0.10), HAL: 48.68 (+0.25), BHI: 63.84 (+0.33)
Stocks Hit New Milestones; BitAuto Rebounds
at Investor's Business Daily - Tue Nov 18, 3:17PM CST
Stocks reached new milestones Tuesday following a mixed performance in the prior session. The Nasdaq made back Monday's loss and then some as it rallied 0.7% to a 14-1/2-year high. The S&P 500 and the Dow Jones industrial average climbed 0.5% and...
AGN: 212.01 (-0.58), VRX: 143.00 (+0.53), ACT: 265.50 (-0.54), BITA: 87.83 (-0.30), BABA: 108.19 (-0.63)
Stock Market Today: Oil Slump Fuels S&P 500 to Fresh Record High
at The Street - Tue Nov 18, 3:09PM CST
Three cheers for the S&P 500 which closed the session at an all-time high for a fifth-consecutive session.
SPLS: 14.03 (+0.11), ACT: 265.49 (-0.55), HD: 96.95 (+0.25), MDT: 71.06 (-0.70), XOM: 95.66 (+0.05), AGN: 212.01 (-0.58), URBN: 30.40 (+0.87), TJX: 62.76 (+0.63), GILD: 101.82 (-0.52), TOT: 58.17 (-0.31), TGT: 71.17 (-1.33), LOW: 62.55 (+0.29), CVX: 116.68 (+0.21)
Zoetis 2015 Guidance Misses As Buyout Theories Abound
at Investor's Business Daily - Tue Nov 18, 2:15PM CST
Animal-health giant Zoetis (ZTS) offered 2015 guidance below the Street's consensus along with longer-term financial goals at its analyst day Tuesday. After a brief halt in trading for the early-afternoon announcement, the stock was down more than 1%...
AGN: 212.01 (-0.58), ZTS: 43.01 (-0.39), ABT: 43.15 (-0.28), ACT: 265.49 (-0.55), VRX: 143.00 (+0.53), PFE: 30.33 (-0.11)
ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
The Crucial Thing You're Missing About Many Dividend Stocks
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 29 mins ago
It's been proved time and time again that investing for the long haul is a better way to build wealth than short-term trading is. It's also been shown that dividend-paying stocks outperform their non-dividend-paying peers. When it comes down to...
ACT: 265.20 (-0.84), PFE: 30.33 (-0.11), AZN: 74.03 (-1.35), BMY: 58.36 (-0.45)
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 55.61 (-0.29), KOG: 10.00 (+0.24), MEAS: 86.00 (+0.01), HHC: 147.57 (+1.65), AET: 85.43 (-0.12), DLPH: 71.03 (-0.07), DLTR: 66.27 (+3.64), AEM: 26.63 (+0.58), AUXL: 33.07 (+0.04), DG: 66.62 (+0.52), ABBV: 65.14 (-0.36), DXM: 8.13 (-0.13), MNK: 84.81 (-1.17), ATHL: 58.40 (unch), NCQ: 0.71 (+0.02), COV: 96.81 (-0.69), AU: 9.61 (+0.27), MYL: 55.14 (-0.54), IAG: 2.28 (+0.07), FDO: 78.47 (+0.02), MGM: 22.16 (-0.03), GNW: 9.18 (+0.05), HIG: 40.71 (-0.09), NG: 2.89 (+0.09), EQIX: 223.23 (-2.45), HSH: 62.96 (unch), OAS: 26.59 (+0.74), PETM: 77.61 (-0.58), ACT: 265.20 (-0.84), MDT: 71.07 (-0.69), BPOP: 31.73 (-0.27), ENZY: 8.64 (+0.24), FCX: 27.97 (-0.11), GFI: 4.37 (+0.28), CZR: 16.22 (+1.85), CVC: 19.03 (+0.10), CIE: 10.44 (+0.31), CACQ: 10.22 (+0.03), AGN: 212.01 (-0.58), ECA: 18.14 (+0.34), FCH: 10.00 (-0.06), R: 90.35 (-0.20), DTV: 87.09 (-0.13), KMDA: 3.40 (+0.01), ANV: 1.68 (+0.19), MOVE: 20.95 (-0.03), BAC: 16.96 (-0.10), GRFS: 36.43 (+0.05), POST: 35.62 (+0.08), HCA: 66.47 (-0.57), RDN: 16.72 (-0.01), BEE: 12.84 (-0.10), CPWR: 10.23 (+0.07), GLD: 114.65 (+0.97), RLGY: 42.71 (-0.23), MTG: 8.96 (-0.01), HMHC: 20.00 (+0.06), CMCSA: 54.38 (unch), CBS: 53.21 (-0.13), BABA: 108.16 (-0.66)
Valeant Rises After Allergan Snub; Zeltiq In Buy Area
at Investor's Business Daily - Wed Nov 19, 5:14PM CST
Valeant Pharmaceuticals (VRX) hasn't missed a beat despite its failed takeover bid for Botox maker Allergan (AGN). Valeant lost out Monday to a competing bid from generic drugmaker Actavis (ACT), which said it would buy Allergan for $66 billion. Yet...
AGN: 212.01 (-0.58), ACT: 265.20 (-0.84), VRX: 143.00 (+0.53), ZLTQ: 28.24 (+0.12)
Mallinckrodt Q4 Earnings Beat Views, But Outlook Hazy
at Investor's Business Daily - Wed Nov 19, 4:35PM CST
Specialty drugmaker Mallinckrodt early Wednesday beat analysts' expectations handily with its fiscal Q4 report, but the stock fell 3.2% after the company put off providing hoped-for guidance in the wake of a Food and Drug Administration decision that...
MNK: 84.81 (-1.17), JNJ: 108.04 (-0.72), ACT: 265.20 (-0.84)
Celgene Up on Encouraging Long-Term Phase III Otezla Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 4:10PM CST
Celgene announced results from long-term efficacy and safety analyses from two phase III studies on Otezla.
ACT: 265.34 (-0.70), AMAG: 34.88 (-0.28), BMY: 58.33 (-0.48), CELG: 106.64 (-0.34)
Mallinckrodt Earnings Beat But No New Guidance
at Investor's Business Daily - Wed Nov 19, 10:42AM CST
Specialty drugmaker Mallinckrodt beat analysts' expectations handily in its fiscal Q4 report, but it didn't provide hoped-for guidance in the wake of an FDA decision that hits one of its best-selling drugs. Mallinckrodt (MNK) stock was down 4% in...
MNK: 84.81 (-1.17), JNJ: 108.04 (-0.72), ACT: 265.34 (-0.70), COV: 96.81 (-0.69)
Stock Market News for November 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 9:10AM CST
Rally in healthcare stocks and easing global growth worries boosted benchmarks to finish in the green on Tuesday
URBN: 30.41 (+0.88), AGN: 212.01 (-0.58), HD: 96.96 (+0.26), ACT: 265.34 (-0.70), GILD: 101.82 (-0.52), PFE: 30.33 (-0.11), COV: 96.81 (-0.69), ALXN: 191.08 (-0.88)
Critical Alerts For Gold Fields, Actavis, Trina Solar Limited, Alcoa and Herbalife Released By InvestorsObserver
PR Newswire - Wed Nov 19, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for GFI, ACT, TSL, AA and HLF.
HLF: 38.54 (-0.12), AA: 16.68 (-0.01), ACT: 265.34 (-0.70), GFI: 4.37 (+0.28), TSL: 10.58 (+0.08)
Cramer's Mad Money - PPG Industries Will Blow Right Through Its All-Time High (11/18/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 19, 4:30AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 18. CEO Interview: Chuck Bunch, PPG Industries (NYSE: PPG ) PPG Industries ( PPG ) has been a consistent performer. It has dominance in the...
AGN: 212.01 (-0.58), GPRO: 73.75 (-5.34), HD: 96.96 (+0.26), ACT: 265.34 (-0.70), BX: 32.59 (-0.08), S: 4.76 (+0.05), HAL: 48.67 (+0.24), M: 62.50 (+0.53), COP: 72.69 (+0.56), GPS: 39.88 (+0.34), BRK.B: 145.13 (-0.52), PPG: 210.74 (+0.08), BHI: 63.84 (+0.33)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 265.34 (-0.70), QLTI: 3.96 (-0.03), VRX: 143.00 (+0.53), AGN: 212.01 (-0.58), SHPG: 207.50 (-0.08), AUXL: 33.07 (+0.04), ABBV: 65.14 (-0.36), SNY: 46.50 (-1.59), ABT: 43.15 (-0.28), ENDP: 69.25 (+0.24), AKRX: 37.81 (-0.37), PFE: 30.33 (-0.11), INCY: 71.18 (-0.12), SLXP: 103.38 (-0.25), MYL: 55.14 (-0.54), AMGN: 162.98 (+0.34), LLY: 66.65 (-0.56), GSK: 46.33 (+0.08), BMY: 58.31 (-0.50), ACHN: 12.91 (unch), MRK: 58.93 (-0.71), AZN: 74.03 (-1.35), ICPT: 154.60 (-1.33), TEVA: 57.24 (-0.01), NVS: 95.21 (-0.52)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 265.34 (-0.70), QLTI: 3.96 (-0.03), VRX: 143.00 (+0.53), AGN: 212.01 (-0.58), SHPG: 207.50 (-0.08), AUXL: 33.07 (+0.04), ABBV: 65.14 (-0.36), SNY: 46.50 (-1.59), ABT: 43.15 (-0.28), ENDP: 69.25 (+0.24), AKRX: 37.81 (-0.37), PFE: 30.33 (-0.11), INCY: 71.18 (-0.12), SLXP: 103.38 (-0.25), MYL: 55.14 (-0.54), AMGN: 162.98 (+0.34), LLY: 66.65 (-0.56), GSK: 46.33 (+0.08), BMY: 58.31 (-0.50), ACHN: 12.91 (unch), MRK: 58.93 (-0.71), AZN: 73.99 (-1.39), ICPT: 154.60 (-1.33), TEVA: 57.24 (-0.01), NVS: 95.21 (-0.52)
Pharma ETFs In Focus On Allergan Takeover Deal
Zacks Funds - at Seeking Alpha - Tue Nov 18, 9:04PM CST
The healthcare space is witnessing 2014 as another banner year thanks to encouraging industry trends, solid corporate earnings and huge levels of merger and acquisition activities. The sector is clearly leading the broad market rally and this trend...
IHE: 146.79 (-0.73), AGN: 212.01 (-0.58), PPH: 64.85 (-0.50), ACT: 265.34 (-0.70), XPH: 109.85 (-0.48)
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous
at The Street - Tue Nov 18, 7:10PM CST
It's hard to be skeptical about high-flying stocks when the bulls are making money right now, Cramer says.
MMM: 158.24 (-0.59), AMZN: 325.43 (-1.11), JEC: 47.60 (+0.40), ACT: 265.34 (-0.70), HD: 96.96 (+0.26), BX: 32.59 (-0.08), DPLO: 25.01 (+0.51), UNH: 96.23 (-0.63), DECK: 94.62 (+0.10), COLM: 43.73 (+0.06), ALKS: 53.85 (-0.41), ADT: 35.41 (+0.04), CELG: 106.64 (-0.34), VE: 17.72 (-0.33), URBN: 30.41 (+0.88), AGN: 212.01 (-0.58), HLT: 25.20 (-0.32), AA: 16.68 (-0.01), RIG: 25.73 (+0.37), WMB: 55.50 (+0.28), PF: 32.99 (+0.09), PPG: 210.74 (+0.08), WPZ: 53.22 (+0.10)
Actavis'
at Investor's Business Daily - Tue Nov 18, 5:42PM CST
Actavis' (ACT) $66 bil takeover of Allergan (AGN) gets activist investor William Ackman's support, said Reuters. Ackman will reportedly withdraw a special shareholder meeting request at Allergan. Actavis shares jumped 8.7% to 269.60. Allergan rose 2%...
AGN: 212.01 (-0.58), ACT: 265.34 (-0.70)
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 265.50 (-0.54), CLDX: 19.52 (+0.79), ABBV: 65.14 (-0.36)
Vipshop, Jack in the Box Rise In After-Hours Trading
at Investor's Business Daily - Tue Nov 18, 4:04PM CST
Stocks finished higher Tuesday, with the Dow Jones industrial average and the S&P 500 making fresh all-time highs and the Nasdaq overcoming Monday's weakness with a 14 1/2-year high. Volume was higher than Monday on the NYSE and slightly lower on the...
AGN: 212.01 (-0.58), JACK: 75.86 (+0.94), ACT: 265.50 (-0.54), VIPS: 22.24 (-0.20)
Market News: Actavis Plc, SunEdison Inc, Halliburton Company
at The Street - Tue Nov 18, 3:54PM CST
Investors' confidence on the U.S. economy increased due to better-than-expected corporate earnings and economic data The stock markets in the United States rallied amid investors' speculation that...
ACT: 265.50 (-0.54), TERP: 31.77 (-0.15), SUNE: 21.63 (+0.10), HAL: 48.68 (+0.25), BHI: 63.84 (+0.33)
Stocks Hit New Milestones; BitAuto Rebounds
at Investor's Business Daily - Tue Nov 18, 3:17PM CST
Stocks reached new milestones Tuesday following a mixed performance in the prior session. The Nasdaq made back Monday's loss and then some as it rallied 0.7% to a 14-1/2-year high. The S&P 500 and the Dow Jones industrial average climbed 0.5% and...
AGN: 212.01 (-0.58), VRX: 143.00 (+0.53), ACT: 265.50 (-0.54), BITA: 87.83 (-0.30), BABA: 108.19 (-0.63)
Stock Market Today: Oil Slump Fuels S&P 500 to Fresh Record High
at The Street - Tue Nov 18, 3:09PM CST
Three cheers for the S&P 500 which closed the session at an all-time high for a fifth-consecutive session.
SPLS: 14.03 (+0.11), ACT: 265.49 (-0.55), HD: 96.95 (+0.25), MDT: 71.06 (-0.70), XOM: 95.66 (+0.05), AGN: 212.01 (-0.58), URBN: 30.40 (+0.87), TJX: 62.76 (+0.63), GILD: 101.82 (-0.52), TOT: 58.17 (-0.31), TGT: 71.17 (-1.33), LOW: 62.55 (+0.29), CVX: 116.68 (+0.21)
Zoetis 2015 Guidance Misses As Buyout Theories Abound
at Investor's Business Daily - Tue Nov 18, 2:15PM CST
Animal-health giant Zoetis (ZTS) offered 2015 guidance below the Street's consensus along with longer-term financial goals at its analyst day Tuesday. After a brief halt in trading for the early-afternoon announcement, the stock was down more than 1%...
AGN: 212.01 (-0.58), ZTS: 43.01 (-0.39), ABT: 43.15 (-0.28), ACT: 265.49 (-0.55), VRX: 143.00 (+0.53), PFE: 30.33 (-0.11)
(0)
(0)Allergan plc (AGN) Stock Research Links
Scroll down for more posts ▼